ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TIBSOVO
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TIBSOVO Rx

Generic Name and Formulations:
Ivosidenib 250mg; tabs.

Company:
Agios Pharmaceuticals

Therapeutic Use:

RECENT UPDATES

Monograph added.

Indications for TIBSOVO:

Treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Adult:

Swallow whole. Take at same time each day. Avoid a high-fat meal. Initially 500mg once daily until disease progression or unacceptable toxicity; treat for a minimum of 6 months to allow time for response. If concomitant strong CYP3A4 inhibitor is unavoidable: reduce to 250mg once daily; when inhibitor is discontinued, resume at 500mg once daily (after at least 5 half-lives of the inhibitor). Monitoring and dose modifications for toxicities: see full labeling.

Children:

Not established.

Boxed Warning:

Differentiation syndrome.

Warnings/Precautions:

Risk of differentiation syndrome (may be fatal if not treated). If differentiation syndrome is suspected, initiate oral or IV corticosteroids and hemodynamic monitoring until resolution; interrupt dose if severe symptoms persist >48hrs after corticosteroid initiation. Assess blood counts/chemistries prior to initiation, at least weekly for the first month, once every other week for the second month, and once monthly thereafter. Monitor creatine phosphokinase weekly for the first month. Monitor ECG at least weekly for the first 3 weeks, then at least monthly thereafter. Congenital long QT syndrome, CHF, electrolyte abnormalities: monitor more frequently. Interrupt therapy if QTc >480–<500msec; interrupt and reduce dose if >500msec; permanently discontinue if QTc prolongation with life-threatening arrhythmias develop. Monitor for new motor and/or sensory neuropathy (eg, unilateral or bilateral weakness, sensory alterations, paresthesias, difficulty breathing); permanently discontinue if Guillain-Barré syndrome diagnosed. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended (during and for at least 1 month after final dose).

Pharmacological Class:

Isocitrate dehydrogenase-1 (IDH1) inhibitor.

Interactions:

See Adults. May increase risk of QT prolongation when concomitant drugs known to prolong QTc interval (eg, antiarrhythmics, fluoroquinolones, triazole antifungals, 5-HT3 receptor antagonists) or with CYP3A4 inhibitors; avoid or use alternatives. Antagonized by strong CYP3A4 inducers; avoid. Antagonizes sensitive CYP3A4 substrates and may antagonize sensitive CYP2C9 substrates; use alternatives or monitor for efficacy if use unavoidable. Concomitant itraconazole or ketoconazole: not recommended. May decrease concentrations of hormonal contraceptives; consider alternatives.

Adverse Reactions:

Fatigue, leukocytosis, arthralgia, diarrhea, dyspnea, edema, nausea, mucositis, QT prolongation, rash, pyrexia, cough, constipation; differentiation syndrome, tumor lysis syndrome, Guillain-Barré syndrome.

Generic Availability:

NO

How Supplied:

Tabs—60

Sign Up for Free e-newsletters